Breast cancer prevention and endocrine risk reduction
Research activity in postmenopausal breast cancer prevention focuses on hormone-related risk reduction, with attention to luminal breast cancer and ductal carcinoma in situ in women at elevated risk.
- Exemestane
- Tamoxifen
- Menopause-related quality of life
The sponsor’s work in this area centers on endocrine approaches relevant to breast tissue biology and symptom burden in women undergoing preventive treatment.
Breast cancer biology and preoperative metabolic intervention
Clinical research also addresses invasive breast cancer and ductal carcinoma in situ through interest in tumor proliferation and metabolic modulation, including studies in the presurgical setting.
- Metformin
- Prolonged nightly fasting
- Ki67 labeling index
This reflects a therapeutic focus on hormone-sensitive breast disease and biological markers linked to tumor activity.
Low-grade serous ovarian carcinoma and gynecologic oncology
The sponsor is involved in research on low-grade serous epithelial ovarian carcinoma, including disease arising in the fallopian tube and peritoneum, with emphasis on ER– and PgR-positive tumors.
- Letrozole
- Hormone receptor-positive ovarian cancer
- Advanced gynecologic malignancy
These studies place endocrine therapy within the management of a rare ovarian cancer subtype with distinct receptor biology.
